



MIT Open Access Articles

Let-7 represses Nr6a1 and a mid-gestation developmental program in adult fibroblasts

The MIT Faculty has made this article openly available. **Please share** how this access benefits you. Your story matters.

Citation	Gurtan, A. M., A. Ravi, P. B. Rahl, A. D. Bosson, C. K. JnBaptiste, A. Bhutkar, C. A. Whittaker, R. A. Young, and P. A. Sharp. "Let-7 Represses Nr6a1 and a Mid-Gestation Developmental Program in Adult Fibroblasts." <i>Genes & Development</i> 27, no. 8 (April 15, 2013): 941–954. Copyright © 2013 by Cold Spring Harbor Laboratory Press
As Published	http://dx.doi.org/10.1101/gad.215376.113
Publisher	Cold Spring Harbor Laboratory Press
Version	Final published version
Citable link	http://hdl.handle.net/1721.1/85578
Terms of Use	Creative Commons Attribution#NonCommercial License
Detailed Terms	http://creativecommons.org/licenses/by-nc/4.0/



Let-7 represses *Nr6a1* and a mid-gestation developmental program in adult fibroblasts

Allan M. Gurtan, Arvind Ravi, Peter B. Rahl, et al.

Genes Dev. 2013 27: 941-954

Access the most recent version at doi:[10.1101/gad.215376.113](https://doi.org/10.1101/gad.215376.113)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2013/04/29/27.8.941.DC1.html>

References

This article cites 68 articles, 23 of which can be accessed free at:
<http://genesdev.cshlp.org/content/27/8/941.full.html#ref-list-1>

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Genes & Development* go to:
<http://genesdev.cshlp.org/subscriptions>

Let-7 represses *Nr6a1* and a mid-gestation developmental program in adult fibroblasts

Allan M. Gurtan,¹ Arvind Ravi,² Peter B. Rahl,³ Andrew D. Bosson,^{1,4} Courtney K. JnBaptiste,^{1,4} Arjun Bhutkar,¹ Charles A. Whittaker,¹ Richard A. Young,³ and Phillip A. Sharp^{1,4,5}

¹David H. Koch Institute for Integrative Cancer Research, Cambridge, Massachusetts 02139, USA; ²Harvard-Massachusetts Institute of Technology Health Sciences and Technology Program, Cambridge, Massachusetts 02139, USA; ³Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA; ⁴Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

MicroRNAs (miRNAs) are critical to proliferation, differentiation, and development. Here, we characterize gene expression in murine Dicer-null adult mesenchymal stem cell lines, a fibroblast cell type. Loss of Dicer leads to derepression of let-7 targets at levels that exceed 10-fold to 100-fold with increases in transcription. Direct and indirect targets of this miRNA belong to a mid-gestation embryonic program that encompasses known oncofetal genes as well as oncogenes not previously associated with an embryonic state. Surprisingly, this mid-gestation program represents a distinct period that occurs between the pluripotent state of the inner cell mass at embryonic day 3.5 (E3.5) and the induction of let-7 upon differentiation at E10.5. Within this mid-gestation program, we characterize the let-7 target *Nr6a1*, an embryonic transcriptional repressor that regulates gene expression in adult fibroblasts following miRNA loss. In total, let-7 is required for the continual suppression of embryonic gene expression in adult cells, a mechanism that may underlie its tumor-suppressive function.

[*Keywords:* Dicer; miRNAs; let-7; embryo; cancer; oncofetal]

Supplemental material is available for this article.

Received February 2, 2013; revised version accepted March 27, 2013.

MicroRNAs (miRNAs) are ~22-nucleotide (nt) RNAs that regulate various processes (Gurtan and Sharp 2013), including organismal development (Bernstein et al. 2003; Harfe et al. 2005), proliferation (Johnson et al. 2005, 2007), and apoptosis (Brennecke et al. 2003; Ghildiyal and Zamore 2009). The seed sequence (positions 2–7) of a miRNA binds the 3' untranslated region (UTR) of a target mRNA, leading to mRNA destabilization and/or translational inhibition (Ghildiyal and Zamore 2009). A single miRNA typically accounts for approximately twofold repression of a target. Due to this mild activity, miRNAs are considered “fine-tuners” of gene expression that act in concert with other classes of regulators (Bartel and Chen 2004). Accordingly, miRNAs shape gene expression by participating in circuits with transcription factors, modulating the kinetics of gene activation or repression, and providing a buffer against perturbation (Herranz and Cohen 2010; Ebert and Sharp 2012).

In vivo, miRNAs are critical to organismal development and survival, while in vitro, miRNAs are dispensable for viability of certain cell lines. In the whole animal, genetic ablation of *Dicer1* or *Dgcr8*, required for miRNA biogenesis, leads to early embryonic lethality and severe differentiation defects (Bernstein et al. 2003; Wang et al.

2007). Similarly, tissue-specific loss of miRNAs during differentiation leads to dysfunction or death in a variety of tissues, including myocytes (O'Rourke et al. 2007), lymphocytes (Muljo et al. 2005; Koralov et al. 2008), and epidermal cells (Andl et al. 2006; Yi et al. 2006). However, global loss of miRNAs is readily tolerated in vitro in various cell types, including embryonic stem cells (ESCs) (Kanellopoulou et al. 2005; Murchison et al. 2005; Calabrese et al. 2007; Wang et al. 2007), murine embryonic fibroblasts (Shapiro et al. 2012), sarcoma cells (Ravi et al. 2012), and immortalized adult mesenchymal stem cells (MSCs) (Gurtan et al. 2012; Ravi et al. 2012).

miRNA-deficient cell lines have been a useful resource for dissecting the role of miRNAs in gene expression programs and cellular phenotypes. Studies of *Dicer1*- and *Dgcr8*-knockout ESCs have elucidated the roles of the ESC-specific miR-290 family in regulating pluripotency networks in conjunction with transcription factors such as *Oct4* (Kanellopoulou et al. 2005; Wang et al. 2007; Marson et al. 2008; Melton et al. 2010). The characterization of these miRNA-deficient ESCs in comparison with their wild-type counterparts or upon add-back of synthetic miRNAs has provided global signatures of activity and furthermore delineated the contribution of a single miRNA family to these signatures.

Few in vitro studies analogous to those in miRNA-deficient ESCs have been reported for somatic cells, which represent a counterpoint to the pluripotent state. The

⁵Corresponding author
E-mail sharp@mit.edu

Article is online at <http://www.genesdev.org/cgi/doi/10.1101/gad.215376.113>.

existing somatic *in vitro* studies have yielded significant insight into the activity of miRNAs in differentiated cell types (Dugas et al. 2010). Many somatic cells predominantly express let-7, a highly conserved miRNA known for its role in opposing self-renewal programs regulated by miR-290 (Melton et al. 2010). In multiple species, ranging from nematodes to mammals, mature let-7 becomes expressed in the developing embryo (Nimmo and Slack 2009; Ambros 2011). In nematodes, loss of the let-7 family results in the reiteration of larval stages. Let-7 is similarly thought to regulate developmental timing in mammals (Schulman et al. 2005). Exogenous expression of mature let-7 in ESCs *in vitro* represses pluripotency programs and antagonizes the activity of the miR-290 family (Melton et al. 2010). *In vivo*, however, the dispersion of let-7 genes across multiple genomic loci has confounded its genetic analysis in mammalian development.

In the adult, mature let-7 persists at high levels and functions as a tumor suppressor (Boyerinas et al. 2010; Trang et al. 2010). Many targets of let-7 are oncogenes, and reduction of let-7 levels is frequently observed in cancer. A small subset of let-7 targets falls into a conceptual class of genes termed “oncofetal” because of their expression profile (Boyerinas et al. 2008; Gurtan and Sharp 2013): highly expressed in the embryo, inactive in most adult tissues, and re-expressed in tumors. The only oncofetal targets of let-7 characterized thus far have been the RNA-binding families *Lin-28a/b* and *Igf2bp1-3* as well as the nonhistone chromatin factor *Hmga2* (Lee and Dutta 2007; Mayr et al. 2007; Boyerinas et al. 2008; Mayr and Bartel 2009). These oncofetal targets regulate proliferation and growth. Transgenic mice that express elevated levels of *Lin-28* are larger than control littermates (Zhu et al. 2010, 2011), while knockouts of *Hmga2* (Zhou et al. 1995) or *Igf2bp1* (Hansen et al. 2004) exhibit dwarf phenotypes. Transgenic overexpression of *Hmga2* (Fedele et al. 2006; Zaidi et al. 2006) or *Igf2bp1* (Tessier et al. 2004) results in tumorigenesis. Given the large number of predicted but uncharacterized targets of let-7, additional genes may populate networks typified by known oncofetal genes.

Here, we exploit a murine Dicer-null somatic cell line to identify gene expression programs regulated by let-7 specifically and somatic miRNAs generally in the context of the adult. Deletion of Dicer in adult MSCs, a fibroblast cell type that abundantly expresses let-7, results in specific, transcriptionally reinforced changes in gene expression, including global derepression of miRNA targets. Dicer-null MSCs largely retain their cellular identity but, within this landscape of mesenchymal gene expression, activate a discrete let-7-targeted mid-gestation developmental program that includes known oncofetal genes as well as oncogenes not previously associated with an embryonic state. Within this mid-gestation program, we characterize the let-7 target *Nr6a1*, an embryonic transcriptional repressor that contributes to gene expression changes in adult fibroblasts following miRNA loss. In total, we report that somatic miRNAs such as let-7 are required for the continual suppression of embryonic gene expression in adult cells, a mechanism that may underlie their tumor-suppressive functions.

Results

Dicer knockout adult fibroblasts exhibit specific changes in gene expression

To understand the role of miRNAs in regulating gene expression in somatic cells, we performed expression profiling in a recently described model of Dicer loss. Specifically, we used immortalized clonal lines of *Dicer1^{fl/fl}* (Dicer wild-type) and *Dicer1^{-/-}* (Dicer knockout) MSCs, a fibroblast cell type present in adult bone marrow (Ravi et al. 2012). To establish a baseline of miRNA expression in these fibroblast cell lines, we performed small RNA sequencing (small RNA-seq) (Supplemental Table S1). In Dicer wild-type MSCs, the five most abundant miRNAs were miR-22 (17%), let-7c (16%), let-7b (9%), miR-16 (7%), and miR-145 (6%). Collapsing miRNAs by seeds, the let-7 family comprised 37% of all miRNA reads, consistent with published observations of let-7 predominance in somatic tissues (Marson et al. 2008). This expression profile is comparable with previous studies in these cells (Gurtan et al. 2012) and closely resembles the profile observed in *Kras^{G12P};Trp53^{-/-};Dicer1^{fl/fl}* sarcoma cells (Ravi et al. 2012). Mature miRNAs constituted 55% of total small RNA reads in Dicer wild-type MSCs but only 0.5% of total reads in Dicer knockout MSCs, similar to the degree of loss observed in sarcoma cells. Per cell, most miRNAs were present at fewer than one copy in Dicer knockout MSCs (Supplemental Fig. S1A). Members of the let-7 family were reduced from thousands of copies per cell in Dicer wild-type MSCs to <10 copies per cell in Dicer knockout MSCs (Supplemental Fig. S1A).

Next, we characterized the consequences of miRNA loss on gene expression. By exon microarray, we observed specific gene expression differences between Dicer wild-type and knockout MSCs (Fig. 1A; Supplemental Table S2), with unsupervised hierarchical clustering distinguishing the cells by genotype (Supplemental Fig. S1B). Two-hundred-seventeen genes were differentially expressed (adjusted *P*-value ≤ 0.1) (Fig. 1A). The median change for both up-regulated and down-regulated genes was approximately threefold (Fig. 1A, gray dashed lines) with a maximum change of ~ 50 -fold.

Conserved targets of conserved miRNAs, as predicted by TargetScan, were largely up-regulated in Dicer knockout MSCs (Fig. 1B), particularly for let-7, miR-199, and miR-15, which are three of the most highly expressed miRNA families in Dicer wild-type MSCs. We also observed Dicer loss-dependent up-regulation of targets of miR-202, which is not expressed in Dicer wild-type MSCs but shares a hexamer seed match with let-7. By gene set enrichment analysis (GSEA), we characterized the enrichment of miRNA target sites in the 3' UTRs of differentially expressed genes. Among genes up-regulated in Dicer knockout MSCs, 37 miRNA motifs were enriched at a false discovery rate (FDR) *q*-value ≤ 0.1 , including let-7 (FDR *q*-value = 0.01) (Supplemental Fig. S1C), miR-199 (FDR *q*-value = 0.02), and miR-15 (FDR *q*-value = 0.03). Among genes down-regulated in Dicer knockout MSCs, only two miRNA seed-match motifs (miR-339 and miR-517)




Figure 1. Loss of Dicer in adult MSCs results in specific gene expression changes. (A) Waterfall plot of genes expressed differentially by exon microarray at an adjusted P -value ≤ 0.1 . Two-hundred-seventeen genes are shown. Dashed gray lines indicate median up-regulation (threefold) and down-regulation (threefold). Two *Dicer1^{fl/fl}* (Dicer wild-type [WT]) and four *Dicer1^{-/-}* (Dicer knockout [KO]) clones were evaluated for gene expression changes. (B) Scatter plot of the median change in expression of miRNA targets relative to control gene sets matched for 3' UTR length, GC content, and expression in Dicer wild-type MSCs. Each point represents conserved targets of a single miRNA seed family. miRNA expression is based on the small RNA-seq data reported in this study. The P -value, whose negative \log_{10} is shown on the X-axis, was calculated by Wilcoxon rank-sum test. (C) Cross-correlation analysis of Dicer wild-type and knockout MSCs versus a cell line panel based on total gene expression by exon microarray. The gene expression of Dicer wild-type and knockout ESCs was published previously (Leung et al. 2011). The gene expression of all other murine cell lines is publicly available from Novartis BioGPS (Wu et al. 2009, 2013). See also Supplemental Figure S1 and Supplemental Tables S1 and S2.

were identified at an FDR q -value ≤ 0.1 . Thus, Dicer loss resulted in derepression of miRNA targets in MSCs.

Dicer knockout fibroblasts retain mesenchymal cell identity

Tissue-specific deletion of Dicer in vivo during development often results in differentiation defects or lethality, suggesting that miRNAs are critical in establishing or maintaining cellular identity. Therefore, we determined whether gene expression changes in Dicer knockout MSCs in vitro reflected a gross change in cellular identity. We compared the full gene expression profiles of Dicer wild-type and knockout MSCs with those of a diverse array of cell types ranging from ESCs to neural cells (Wu et al. 2009, 2013). Cells generally clustered by cell type, and the profile of Dicer wild-type MSCs correlated most closely with mesenchymal cells such as 3T3-L1 and C3H10(1/2) cells (Fig. 1C). Dicer knockout MSCs remained mesenchymal, correlating most closely with Dicer wild-type MSCs. Thus, MSCs retain their identity independent of miRNAs.

To test whether this observation could be extended to another cell type, we also analyzed Dicer wild-type and knockout ESCs generated from the same Dicer-conditional mouse model (Leung et al. 2011). Both Dicer wild-type and knockout ESCs correlated closely with independently derived, wild-type ESCs in the panel and clustered separately from differentiated cell types (Fig. 1C). In total, loss of miRNAs does not result in gross changes in pre-established cellular identity.

Dicer knockout fibroblasts exhibit a *let-7*-regulated oncofetal signature

Dicer knockout MSCs exhibit signatures for numerous miRNAs. From among these signatures, we focused on *let-7* because it is an abundant tumor suppressor that represents the somatic counterpoint to the ESC-specific miR-290 family. In Dicer knockout MSCs, the top two statistically significant up-regulated genes were the oncofetal *let-7* targets *Igf2bp1* (up 48-fold by microarray) and *Igf2bp2* (up 16-fold). By quantitative PCR (qPCR), we confirmed the up-regulation of these genes as well as *Igf2bp3* and *Hmga2*, two additional oncofetal genes and targets of *let-7* (Fig. 2A). The large magnitude of up-regulation for all four genes was striking, ranging by qPCR from 11-fold for *Hmga2* to 300-fold for *Igf2bp2*. Similarly, by Western blot, these genes were largely undetectable at the protein level in Dicer wild-type MSCs but became highly expressed in Dicer knockout MSCs (Fig. 2B). All four genes are *let-7* targets, demonstrated by their down-regulation at the mRNA and protein levels by transfection with an siRNA duplex of *let-7g* (Fig. 2A,B). In contrast, neither *Lin28a* nor *Lin28b* was expressed in Dicer wild-type or knockout MSCs (Supplemental Table S2), suggesting that factors in addition to miRNA loss contribute to up-regulation of oncofetal genes.

Due to the magnitude of gene expression changes for these genes, we tested whether transcription contributes to this oncofetal signature. We carried out chromatin immunoprecipitation (ChIP) coupled with sequencing (ChIP-seq) for H3K4me3 and H3K36me3, associated with

Gurtan et al.




Figure 2. Dicer knockout (KO) MSCs up-regulate oncofetal genes. (A,B) qPCR (A) and Western blot analysis (B) of oncofetal genes. p107 is shown as a loading control for Western blot. Error bars indicate standard error of the mean (\pm SEM). (C) Normalized read counts for chromatin marks at *Igf2bp1* for Dicer wild-type (WT) and knockout MSCs. Two replicates (r1 and r2) are shown per sample. Within each chromatin mark (H3K4me3, H3K36me3, and H3K27me3), all samples are set to the same scale. Flanking genes are shown as controls. (D) Box plot of log₂ fold change in gene expression for all genes ("All"), all predicted let-7 targets ("Let-7"), genes enriched in H3K4me3 in Dicer knockout MSCs relative to Dicer wild-type MSCs ("H3K4me3 in Dicer KO"), or overlapping genes from the latter two categories ("Let-7, H3K4me3 in Dicer KO"). P-values were calculated with a Wilcoxon rank-sum test. See also Supplemental Figure S2 and Supplemental Tables S2 and S3.

transcriptionally active genes, and H3K27me3, associated with transcriptionally inactive genes (Supplemental Table S3). We confirmed that genes associated with H3K4me3 and H3K36me3 marks were expressed highly at the mRNA level relative to all genes, while genes associated with H3K27me3 were expressed lowly relative to all genes (Supplemental Fig. S2A,B).

We inspected oncofetal genes for changes in these histone marks. For *Igf2bp1* (Fig. 2C), *Igf2bp2* (Supplemental Fig. S2E), and *Igf2bp3* (Supplemental Fig. S2F), we observed broad peaks of H3K27me3 in Dicer wild-type MSCs, supporting the observation that these genes are "off" in miRNA-expressing cells. Conversely, in Dicer knockout MSCs, all three genes exhibited a loss of H3K27me3 and concomitant gains in promoter-associated H3K4me3 and gene body-associated H3K36me3, demon-

strating transcriptional activation of this family of genes. In comparison, the ChIP-seq density for four flanking genes (*Tra2a*, *Tra2b*, *Snf8*, and *Gip*) was indistinguishable between Dicer wild-type and knockout cells, consistent with the observation that these control genes are not differentially expressed upon Dicer loss (mean fold change = 1.0, mean adjusted P-value = 0.88). Although *Lin28a* and *Lin28b* lost H3K27me3 density in Dicer knockout MSCs, they did not exhibit any detectable peaks of either H3K4me3 near their promoters or H3K36me3 in their gene bodies, suggesting that these two oncofetal genes are not transcriptionally activated, consistent with the absence of their expression by microarray.

A more global comparison of histone marks between genotypes also revealed Dicer-dependent changes in chromatin. Several thousand genotype-specific peaks for

H3K4me3 and H3K36me3 were enriched in one genotype relative to the other (Supplemental Table S3). Specifically, 205 and 981 genes were marked with genotype-specific H3K4me3 peaks in Dicer wild-type and Dicer knockout MSCs, respectively, and generally exhibited higher expression in their respective genotypes (Supplemental Fig. S2C). Similarly, 357 and 147 genes were marked with genotype-specific H3K36me3 peaks in Dicer wild-type and Dicer knockout MSCs, respectively, and generally exhibited higher expression in their respective genotypes (Supplemental Fig. S2D).

To determine whether transcription contributes to up-regulation of let-7 targets generally, we examined the expression of the overlap between predicted let-7 targets (813 genes) and genes enriched for H3K4me3 in Dicer knockout relative to Dicer wild-type MSCs (981 genes). These genes (63 genes) (Supplemental Table S7, "Let-7, H3K4me3 in Dicer KO"), which include the *Igf2bp1-3* family but not *Hmga2*, were more highly expressed than all predicted let-7 targets (Fig. 2D, cf. "Let-7" and "Let-7, H3K4me3 in Dicer KO") or all genes enriched for H3K4me3 in Dicer knockout relative to Dicer wild-type (Fig. 2D, cf. "H3K4me3 in Dicer KO" and "Let-7, H3K4me3 in Dicer KO"). In total, oncofetal let-7 targets are up-regulated, with transcriptional increases, in Dicer knockout MSCs.

Add-back of let-7 to Dicer knockout fibroblasts identifies direct targets

To expand our analysis of let-7 beyond known oncofetal targets and validate additional targets among computational predictions, we experimentally identified targets by reconstituting let-7 expression in Dicer knockout MSCs. To do so, we carried out mRNA sequencing (mRNA-seq) on polyA-selected total RNA isolated 48 h after transfection of Dicer wild-type MSCs with non-targeting control siRNA (siCtrl) or transfection of Dicer knockout MSCs with either siCtrl or synthetic let-7g siRNA duplex as a representative member of the let-7 family (Supplemental Table S4).

Comparison of Dicer wild-type and knockout MSCs by mRNA-seq recapitulated the exon microarray results and demonstrated specific gene expression changes with Dicer loss (Supplemental Fig. S3A). Relative to control-transfected Dicer wild-type MSCs, 1783 genes (FPKM [fragments per kilobase of exon per million fragments mapped] cutoff ≥ 0.1 , q -value < 0.05) were up-regulated in control-transfected Dicer knockout MSCs with a median fold change of ~ 2 , while 1746 genes (FPKM cutoff ≥ 0.1 , q -value < 0.05) were down-regulated with a median fold change of ~ 2 (Supplemental Fig. S3A). miRNA targets were largely derepressed in Dicer knockout MSCs relative to Dicer wild-type MSCs (Supplemental Fig. S3B). More genes were differentially expressed by mRNA-seq than by exon microarray, probably due to the sensitivity of sequencing and the use of a single pair of Dicer wild-type and knockout clones in the mRNA-seq experiment, thus eliminating clonal heterogeneity.

Add-back of let-7 to Dicer knockout MSCs induced many changes in gene expression, including down-regulation

of 1233 genes (FPKM cutoff ≥ 0.1 , q -value < 0.05), with a median fold change of ~ 2 , and the up-regulation of 1993 genes (FPKM cutoff ≥ 0.1 , q -value < 0.05), with a median fold change of ~ 2 (Fig. 3A; Supplemental Fig. S3C). Let-7g-transfected cells clustered more closely with siCtrl-transfected Dicer knockout MSCs than with siCtrl-transfected Dicer wild-type MSCs, indicating that changes in addition to let-7 loss, such as miR-15-loss or miR-199-loss, contribute to the gene expression profile of Dicer loss (Supplemental Fig. S3D).

Analysis of expression changes of all predicted miRNA targets revealed a strong let-7 signature in let-7g-transfected Dicer knockout MSCs. The moving average of the TargetScan score for predicted let-7 targets increased significantly among genes that were most highly expressed in Dicer knockout siCtrl cells relative to siCtrl-transfected Dicer wild-type and let-7g-transfected Dicer knockout MSCs (Fig. 3A, side plot). In contrast, no signal was observed in this moving average for predicted targets of miR-15, indicating specificity of the let-7g siRNA. Global analysis of median gene expression changes in Dicer knockout MSCs transfected with let-7g revealed statistically significant signals for targets of let-7; miR-202, which shares a 6-mer seed with the let-7 family; and miR-196, whose seed sequence begins at position 2 of the let-7 seed sequence and thus is a seed-shifted relative of let-7 (Supplemental Fig. S3E). GSEA confirmed down-regulation of let-7 targets upon transfection of let-7g siRNA (Supplemental Fig. S3F).

Add-back of let-7 should result in two types of changes: (1) direct repression of let-7 targets and (2) secondary effects downstream from let-7 targets, including genes induced by let-7 add-back. To identify targets repressed directly by let-7, we overlapped genes that were up-regulated following Dicer loss by mRNA-seq at q -value < 0.05 (Fig. 3B, left panel, "Derepressed in Dicer KO"), down-regulated with add-back of let-7g at q -value < 0.05 (Fig. 3B, left panel, "Repressed with let-7 add-back in Dicer KO"), and predicted by TargetScan to be let-7 targets (Fig. 3B, left panel, "Predicted targets of let-7"). This triple overlap identified 122 genes (listed in Supplemental Table S7) that included *Hmga2* and the *Igf2bp1-3* family discussed above, an enrichment of 28-fold above background. We randomly selected seven genes from this set for validation by qPCR and, for all seven genes, confirmed up-regulation upon Dicer loss and down-regulation following transfection of let-7g (Fig. 3C). However, repression of predicted targets by add-back of let-7 was only partially reversible and may reflect either transcriptional effects, a requirement for cotargeting by additional seed families, or transfection of synthetic let-7 at a concentration below endogenous levels. Hereafter, we refer to this set of 122 genes as "high-confidence" targets of let-7.

To test whether up-regulation of "high-confidence" targets could be generalized to a second cell type, we analyzed microarray gene expression data (Supplemental Table S5) from sarcoma cell lines that are *Kras*^{G12D}; *Trp53*^{-/-}; *Dicer1*^{+/+} (heterozygous) and in which let-7 is the most abundant seed family or *Kras*^{G12D}; *Trp53*^{-/-}; *Dicer1*^{-/-} (knockout) (Ravi et al. 2012). Indeed, "high-confidence"

Gurtan et al.




Figure 3. Identification of let-7 targets by let-7 add-back to Dicer knockout (KO) MSCs. (A) Heat map of expression Z-scores in transfected Dicer wild-type (WT) and knockout MSCs for all genes expressed at FPKM ≥ 0.1 . Genes are ranked from highest (*top*) to lowest (*bottom*) Z-score in Dicer knockout MSCs. A 10-gene moving average of TargetScan scores is shown in the *left* plot for let-7 (black) and miR-15 (gray). (B) Overlap of genes up-regulated at q -value < 0.05 in siCtrl-transfected Dicer knockout MSCs relative to siCtrl-transfected Dicer wild-type MSCs (“De-repressed in Dicer KO”), down-regulated at q -value < 0.05 in let-7g-transfected Dicer knockout MSCs relative to siCtrl-transfected Dicer knockout MSCs (“Repressed with let-7 add-back in Dicer KO”), and predicted by TargetScan to be conserved targets of let-7 (“Predicted targets of let-7”). Top predicted let-7 targets in TargetScanMouse are shown in the table on the *right*. (C) qPCR analysis of high-confidence targets of let-7 identified in triple overlap *above*. Error bars indicate the SEM. (D) Metaplot of CLIP-seq read density. CLIP-seq reads were aligned to TargetScan-predicted sites. The average CLIP-seq read coverage per gene was plotted relative to let-7 target sites within the 3' UTRs of high-confidence targets of let-7 (“HC, let-7”), let-7 target sites within the 3' UTRs of all TargetScan-predicted targets of let-7 (“All, let-7”), or miR-124 target sites within the 3' UTRs of all TargetScan-predicted targets of let-7 (“All, miR-124”). The analysis was carried out for genes with FPKM ≥ 0.1 in either Dicer wild-type or knockout MSCs transfected with siCtrl. (E) CLIP-seq density along the 3' UTR of *Nr6a1*. The blue histogram indicates CLIP-seq density; gray tick marks indicate the location of TargetScan-predicted, conserved let-7 sites; and orange tick marks indicate the location of TargetScan-predicted, nonconserved let-7 sites. The length of the 3' UTR is indicated. See also Supplemental Figures S3 and S4 and Supplemental Tables S4 and S6.

targets of let-7 were largely up-regulated with Dicer loss in sarcoma cells relative to control genes (Supplemental Fig. S3G). The oncofetal genes *Igf2bp1* and *Igf2bp3* were strongly up-regulated, as were many of the genes that we validated in MSCs by qPCR (Supplemental Fig. S3H, note the logarithmic Y-axis). Up-regulation of *Hmga2* and *Igf2bp2* was not observed in sarcoma cells, likely due to already high basal expression in muscle (Li et al. 2012), the tissue type from which these cells were derived.

Thus far, we defined “high-confidence” targets of let-7 based on gene expression. To determine whether these

genes are directly bound by the RNA-induced silencing complex (RISC) loaded with let-7, we carried out cross-linked immunoprecipitation (CLIP) sequencing (CLIP-seq) (Chi et al. 2009). To do so, we infected Dicer wild-type MSCs with lentivirus encoding doxycycline-inducible Flag-HA-Ago2 or untagged Ago2 as a negative control, selected transduced cells with hygromycin, and induced transgene expression with doxycycline. We then sequenced UV-cross-linked RNA that was isolated from Flag-HA-Ago2- and untagged Ago2-expressing cells by sequential anti-Flag and anti-HA immunoprecipitation (Supplemental Table S6).

In Flag-HA-Ago2-expressing cells, a metagene plot at TargetScan-predicted, conserved let-7 target sites demonstrated higher CLIP-seq signal per gene for “high-confidence” let-7 targets compared with all conserved TargetScan let-7 targets expressed ≥ 0.1 FPKM (Wilcoxon rank-sum test P -value = 1.4×10^{-22}) (Fig. 3D). In contrast, no peak in signal was observed at target sites of miR-124, a miRNA not expressed in MSCs, within TargetScan-predicted let-7 targets (Fig. 3D) or at let-7 sites in CLIP-seq carried out from cells expressing untagged Ago2 (data not shown). Inspection of individual 3' UTRs demonstrated CLIP-seq peaks at both conserved and nonconserved TargetScan-predicted let-7 sites for *Nr6a1* (Fig. 3E), a gene characterized in further detail below. We also observed peaks at let-7 target sites within the 3' UTRs of *Igf2bp1* (Supplemental Fig. S4A), *Arid3a* (Supplemental Fig. S4B), *Pbx3* (Supplemental Fig. S4C), and numerous other genes, including those validated in Figure 3C.

Approximately 78% of “high-confidence” targets of let-7 exhibited five or more reads within 5 nt of their predicted let-7 target sites. For all TargetScan targets, ~63% of genes exhibited five or more reads at predicted let-7 target sites. In contrast, for both “high-confidence” let-7 targets and all predicted let-7 targets, only ~30% of genes possessing target sites for miR-124 exhibited five or more reads at predicted miR-124 sites. CLIP-seq from Dicer wild-type MSCs likely underestimates binding of the RISC to those genes that are not transcribed or are very lowly expressed. For example, *Igf2bp2*, validated previously (Alajez et al. 2012), and *Igf2bp3* are more strongly repressed than *Igf2bp1* upon let-7 add-back but are below the five-read cutoff by CLIP-seq in Dicer wild-type MSCs. For multiple genes, CLIP-seq peaks were also observed at predicted sites for miRNAs other than let-7, indicating regulation by multiple miRNA seed families. In total, we experimentally identified numerous let-7 targets functionally by let-7 add-back to Dicer knockout MSCs and independently confirmed that these genes are strongly enriched for Ago2-binding at let-7 sites.

Let-7 targets comprise a mid-gestation embryonic program

Since miRNAs may regulate networks of functionally related genes, we examined whether “high-confidence” targets of let-7 possess any common characteristics. Many of these genes, such as *Igf2bp1–3*, *Hmga2*, *Pbx3*, and *Arid3b*, are known to be expressed in the embryo (Hirning-Folz et al. 1998; Hansen et al. 2004; Takebe et al. 2006; Vitobello et al. 2011), in line with the hypothesis that mammalian let-7 regulates development. We also identified numerous oncogenes, including *Plagl2*, which is overexpressed in glioma and colorectal cancer (Zheng et al. 2010), and *Arid3a*, which drives bypass of RAS-induced senescence (Peeper et al. 2002). Furthermore, several “high-confidence” let-7 targets, including but not limited to *Plagl2*, *Arid3a*, and oncofetal genes, are known to peak in expression around mid-gestation (approximately embryonic day 8.5 [E8.5] to E10.5). Importantly, this timing distinguishes these genes from *Oct4* and

other pluripotency markers that are expressed in ESCs, down-regulated upon differentiation, and inactive in Dicer knockout MSCs.

To systematically determine whether “high-confidence” targets of let-7 exhibit a mid-gestation embryonic signature, we profiled these genes in a published time course of gene expression in whole mouse embryos (Irie and Kuratani 2011). We restricted our analysis to genes that were expressed in at least one of the time points in the data set. The majority of “high-confidence” targets of let-7, including *Hmga2* and the *Igf2bp1–3* family, are expressed mid-gestation and steadily decrease as embryogenesis progresses (Fig. 4A). To quantify these changes, we plotted the mean Z-score for each gene (the expression of each gene at each time point normalized to the mean expression and standard deviation of the gene across all time points). These genes peak in expression at E8.5–E10.5 and subsequently decline (Fig. 4B), thus anti-correlating with the expression of let-7, which becomes detectable by Northern blot in whole mouse embryos at E10.5, plateaus by E14.5, and remains high postnatally (Fig. 4B–E, dashed line; Schulman et al. 2005). In contrast, the set of all conserved let-7 targets predicted by TargetScan and expressed in at least one time point in the whole mouse embryo data set was largely indistinguishable from background (Fig. 4C). We confirmed the anti-correlation between let-7 and its “high-confidence” targets in a second, independent published time course of mouse embryonic limb bud development (Taher et al. 2011). As before, the majority of “high-confidence” targets decreased as the embryonic limb bud developed (Supplemental Fig. S5A). On average, these genes anti-correlated with let-7 (Supplemental Fig. S5B), while, in contrast, the set of all conserved let-7 targets predicted by TargetScan was largely indistinguishable from background (Supplemental Fig. S5C). In total, members of the “high-confidence” let-7 target set peak in expression around E8.5 and anti-correlate with let-7 during development.

Add-back of let-7 in Dicer knockout MSCs also induces the expression of many genes, which are likely “indirect targets” downstream from genes repressed directly by let-7. In the whole mouse embryo, we tested whether “indirect targets” of let-7 exhibited a specific pattern. “Indirect targets” were induced as the embryo matured, correlating positively with let-7 and anti-correlating with “high-confidence” targets of let-7 (Fig. 4D). This positive correlation was also observed in the mouse embryonic limb bud (Supplemental Fig. S5D). In total, let-7 controls a mid-gestation embryonic program in somatic cells by directly repressing genes that peak mid-gestation and indirectly inducing genes that become activated as the embryo matures.

Nr6a1, an embryonic transcriptional repressor, is a target of let-7 and represses gene expression in Dicer knockout MSCs

The gene *Nr6a1*, also known as *Germ cell nuclear factor (GCNF)*, was notable among “high-confidence” let-7 targets, since it meets the criteria of a classical developmental target of let-7. *Nr6a1* is an embryonically expressed

Gurtan et al.





Figure 4. Let-7 targets are dynamically expressed in the whole mouse embryo. (A) Heat map of individual high-confidence let-7 targets in the whole mouse embryo from E7.5 to E18.5 (Irie and Kuratani 2011). Genes validated by qPCR in this study are labeled on the *right*. (B–E) Average expression Z-score for high-confidence let-7 targets (B), all predicted conserved TargetScan targets of let-7 (C), indirect targets of let-7 (D), and *Nr6a1* (E) in the whole mouse embryo from E7.5–E18.5 (Irie and Kuratani 2011). The black dashed line shows let-7 expression. Error bars indicate the SEM. See also Supplemental Figure S5.

sequence-specific transcriptional repressor and orphan nuclear receptor (Fuhrmann et al. 2001). Like many targets of let-7, such as the nematode nuclear steroid receptor *daf-12* (Hammell et al. 2009), *Nr6a1* is critical to development, during which it inhibits the pluripotency factor *Oct4* (Gu et al. 2005). Germline deletion of *Nr6a1* results in embryonic lethality mid-gestation due to failures in neural tube closure and somitogenesis (Chung et al. 2001). *Nr6a1* is the top-predicted target of let-7 by TargetScan and possesses eight let-7 seed matches in its 3' UTR (Fig. 3B, right panel). By qPCR, we confirmed up-regulation of *Nr6a1* with miRNA loss and its down-regulation following add-back of let-7 (Fig. 3C, boxed in red). Similarly, *Nr6a1* is up-regulated 10-fold in Dicer knockout sarcoma cells (Supplemental Fig. S3H). We also demonstrated its interaction with the RISC at predicted let-7 target sites (Fig. 3E), indicating that *Nr6a1* is a direct target of let-7. Finally, *Nr6a1* is part of the mid-gestation signature regulated by let-7, with a peak in expression around E8.5 and a subsequent decrease anti-correlating with let-7 in the whole mouse embryo (Fig. 4E) and in the mouse embryonic limb bud (Supplemental Fig. S5E).

Having identified the transcriptional repressor *Nr6a1* as part of a mid-gestation program regulated by let-7 in adult fibroblasts, we combined knockdown and over-expression experiments to determine whether *Nr6a1* in turn regulates gene expression in Dicer knockout MSCs

(Fig. 5A; Supplemental Table S4). We transfected Dicer knockout MSCs, which are “NR6A1-high,” with siRNA against *Nr6a1* (Supplemental Fig. S6A) and profiled gene expression by mRNA-seq (Supplemental Fig. S6B). With a knockdown efficiency of ~75%, we observed differential expression of 1601 genes (FPKM cutoff ≥ 0.1 , q -value < 0.05). Of these, 978 were up-regulated with a median fold change of 1.8 (Supplemental Fig. S6B). The observation that depletion of NR6A1 results in majority up-regulation of genes suggests that NR6A1 acts as a transcriptional repressor in Dicer knockout MSCs.

Next, to identify genes directly regulated by NR6A1 and uncouple it from accompanying gene expression changes observed with Dicer loss, we overexpressed Flag-HA-NR6A1 in Dicer wild-type MSCs (Supplemental Fig. S6C), which are “NR6A1-low.” By mRNA-seq, we observed differential expression of 104 genes (FPKM cutoff ≥ 0.1 , q -value < 0.05), of which a majority were down-regulated with a median change of 5.5-fold (Supplemental Fig. S6D), consistent with a transcriptionally repressive activity for NR6A1. Next, we characterized the expression of these Flag-HA-NR6A1-responsive genes in Dicer knockout MSCs. To do so, we restricted our analysis to genes differentially expressed at a q -value < 0.05 within each data set and expressed at an FPKM ≥ 0.1 across all three data sets (leading to a total of 76 genes responsive to expression of Flag-HA-NR6A1, 1556 genes responsive to knockdown of



Nr6a1, and 3431 genes responsive to Dicer loss). Flag-HA-NR6A1-responsive genes, listed in Supplemental Table S7, were largely repressed in Dicer knockout MSCs (Fig. 5B) and subsequently induced in Dicer knockout MSCs following knockdown of *Nr6a1* (Fig. 5C), demonstrating that *Nr6a1* is responsible for their down-regulation with miRNA loss. Thirty-two genes, defined hereafter as “NR6A1-responsive,” were common in the overlap of changes observed upon overexpression of Flag-HA-NR6A1, loss of Dicer, and knockdown of endogenous *Nr6a1* (Fig. 5D; Supplemental Table S7), representing an enrichment of 12-fold over background. Of these 32 genes, 13 were also responsive to let-7 (Supplemental Table S7). This partial overlap suggests that the activity of *Nr6a1* is not restricted to targets of let-7. Notably, given that *Nr6a1* is a transcriptional repressor, it is unlikely to account for the transcriptional induction of let-7 targets, such as *Igf2bp1*, observed in Dicer knockout MSCs. Furthermore, overexpression of *Nr6a1* alone in Dicer wild-type MSCs, which are “*Nr6a1*-low,” results in the differential expres-

Figure 5. Gain-of-function and loss-of-function approaches identify genes regulated by let-7 target NR6A1. (A) Schematic of experimental design. (From left) Dicer wild-type (WT) MSCs (“NR6A1-low”) were infected with pMMP-puro retrovirus encoding vector control or Flag-HA-NR6A1, selected with puromycin, and passaged for several weeks prior to isolation of total RNA for polyA-selected mRNA-seq. (From right) Dicer knockout (KO) MSCs (“NR6A1-high”) were transfected with control nontargeting siRNA (siCtrl) or siRNA against *Nr6a1* (siNR6A1) 48 h prior to isolation of total RNA for polyA-selected mRNA-seq. (B) Box plot of gene expression changes in siCtrl-transfected Dicer knockout versus siCtrl-transfected Dicer wild-type MSCs for all genes (“All genes”) or genes differentially expressed upon overexpression of Flag-HA-NR6A1 (“Flag-HA-NR6A1-responsive”). An FPKM cutoff ≥ 0.1 was used for all compared data sets. *P*-value was calculated by Wilcoxon rank-sum test. (C) Box plot of gene expression changes in siNR6A1-transfected Dicer knockout versus siCtrl-transfected Dicer knockout MSCs for all genes (“All genes”) or genes differentially expressed upon overexpression of Flag-HA-NR6A1 (“Flag-HA-NR6A1-responsive”). An FPKM cutoff ≥ 0.1 was used for all compared data sets. *P*-value was calculated by Wilcoxon rank-sum test. (D) Triple overlap of Flag-HA-NR6A1-responsive, NR6A1 knockdown-responsive, and Dicer deletion-responsive gene sets. (E) Average Z-score in the whole mouse embryo time course for 32 NR6A1-responsive genes defined in D. The orange dashed line shows *Nr6a1* expression, and the black dashed line shows let-7 expression. Error bars indicate the SEM. See also Supplemental Figure S6 and Supplemental Table S4.

sion of ~ 100 genes, in contrast to the >1000 transcriptional changes that we observed with Dicer loss. These observations suggest that other miRNA-regulated factors in addition to or in place of *Nr6a1* contribute to changes in histone marks.

Since *Nr6a1* is normally expressed during development, we examined the embryonic expression of NR6A1-responsive genes. These genes correlated inversely with *Nr6a1*, with low expression mid-gestation that increased as the whole mouse embryo (Fig. 5E) and embryonic limb bud (Supplemental Fig. S6E) matured. In total, we identified *Nr6a1* as a let-7 target that mediates secondary transcriptional gene expression changes in Dicer knockout MSCs.

Genome-wide binding profile identifies direct targets of NR6A1

Having identified genes functionally responsive to *Nr6a1*, we next carried out ChIP-seq of Flag-HA-NR6A1 to

Gurtan et al.

identify genes that are directly bound (Supplemental Fig. S7A; Supplemental Tables S3, S7). We identified 9223 enriched regions, corresponding to a total of 5210 bound or nearby genes (Fig. 6A). Approximately 19% of peaks overlapped with promoters, defined as regions spanning 5 kb upstream of to 1 kb downstream from annotated transcription start sites (TSSs); 38% of peaks were in gene bodies; and 43% of peaks were intergenic (Fig. 6A,C). Peaks in all three categories were strongly enriched for the sequence CAAG(G/T)TCA (Fig. 6B), reported previously to be part of the consensus recognized by NR6A1 (Yan et al. 1997). We also identified additional enriched sequences (Supplemental Fig. S7B) that may be recognized by interacting partners of NR6A1. Interestingly, Flag-HA-NR6A1 was bound to three oncofetal genes (*Hmga2*, *Igf2bp2*, and *Igf2bp3*), suggesting cross-regulation of genes within mid-gestation programs. However, the mRNA levels of these oncofetal genes did not change upon induction of Flag-HA-NR6A1 or knockdown of *Nr6a1*, suggesting the presence of additional regulators responsible for their differential expression.

Of the 32 NR6A1-responsive genes that were repressed in Dicer knockout cells and derepressed following knockdown of NR6A1, 26 were bound by NR6A1 (Supplemental Table S7), representing an enrichment of 2.6-fold over

background (χ^2 test, P -value = 6.0×10^{-7}) (Supplemental Fig. S7C), and nine of these genes possessed the NR6A1 consensus motif in either the promoter, gene body, or distal intergenic region. Among the 32 NR6A1-responsive genes (Fig. 6D, "Responsive"), those that were bound by NR6A1 (Fig. 6D, "Responsive, bound") were more strongly repressed upon overexpression of Flag-HA-NR6A1, particularly if the binding site possessed the NR6A1 consensus motif (Fig. 6D, "Responsive, bound, motif"). Genes bound by NR6A1, especially in regions containing the consensus site, were more strongly derepressed upon knockdown of NR6A1 in Dicer knockout MSCs (Fig. 6E). Finally, NR6A1-bound genes that were repressed upon overexpression of Flag-HA-NR6A1 anti-correlated with NR6A1 in the whole mouse embryo (Supplemental Fig. S7D) and in the mouse embryonic limb bud (Supplemental Fig. S7E). In total, these results identify direct targets of NR6A1 in MSCs and demonstrate the anti-correlation of these targets with NR6A1 expression during embryonic development.

Discussion

We characterized gene expression in immortalized bone marrow-derived Dicer-deficient somatic fibroblasts and




Figure 6. Global genomic profile of NR6A1 binding. (A) Summary of binding data for Flag-HA-NR6A1. In total, 9223 sites are bound genome-wide and map to either promoter-proximal (5 kb upstream of to 1 kb downstream from the TSS), genic (excluding promoter-proximal regions), or intergenic regions. Associated genes were defined as those genes proximal to promoter peaks, overlapping with genic peaks, or closest to intergenic peaks. In total, 5210 genes are associated with or near Flag-HA-NR6A1-binding sites. The called regions represent the intersection of two clonal replicates. (B) Motifs identified by DREME analysis in each category (promoter, genic, and intergenic) summarized in A. The motifs are ranked by enrichment score (E -value) within each category (rank in category). The published motif is also shown (Yan et al. 1997). (C) Normalized read counts of two clonal replicates (r1 and r2) of vector control or Flag-HA-NR6A1 at *Nmnat3*, a gene responsive to Flag-HA-NR6A1 overexpression, NR6A1 knockdown, and Dicer loss. The promoter-proximal site includes two tandem NR6A1 consensus motifs (shown above the read counts). A flanking gene is shown as a control. (D,E) Box plots of gene expression changes in Flag-HA-NR6A1-overexpressing Dicer wild-type (WT) MSCs versus vector-only Dicer wild-type MSCs (D) or siNR6A1-transfected Dicer knockout (KO) versus siCtrl-transfected Dicer knockout MSCs (E) for all genes ("All genes"), the 32 genes responsive to NR6A1 as defined by triple overlap ("Responsive"), genes responsive to and bound by NR6A1 ("Responsive, bound"), or the subset of NR6A1 consensus motif-containing genes responsive to and bound by NR6A1 ("Responsive, bound, motif"). See also Supplemental Figure S7 and Supplemental Tables S3 and S4.

observed large-magnitude changes in gene expression following loss of miRNAs. A subset of these effects was reinforced transcriptionally, notably for three archetypal oncofetal genes (*Igf2bp1–3*), indicating that the large fold changes observed in Dicer knockout MSCs for this family are attributable to not only disruption of miRNA–mRNA interactions (often responsible for only modest effects), but also transcriptional feedback that amplifies expression of let-7 targets. Hence, microscale “fine-tuning” activity at the level of miRNA–mRNA interactions masks, in aggregate, macro-level transcriptional effects on gene expression.

Dicer knockout MSCs retain their mesenchymal identity, indicating that miRNAs do not primarily govern pre-established cell identity. This finding, in conjunction with the requirement for miRNAs during active differentiation and development, suggests a role for miRNAs primarily in the transition between cell states. Consistent with this possibility, miRNAs modulate the dynamics of gene expression to regulate cellular transitions and physiological robustness in numerous model systems (Herranz and Cohen 2010; Ebert and Sharp 2012). If the nearly universally reported stress sensitivity of miRNA-deficient cells is reframed as a general requirement for miRNAs in stimulus response, regardless of the nature of the stimulus, then the observation that miRNA loss results in embryonic lethality is consistent with the notion that miRNA-deficient cells cannot respond properly to developmental stimuli.

In the context of the immortalized cell lines reported here, let-7 represses an embryonic program distinct from pluripotency and related instead to a mid-gestation network that may regulate proliferative and metabolic pathways. In addition to known oncofetal let-7 targets, this program includes oncogenes that have not previously been associated with embryonic development or let-7, such as *Plagl2* (Zheng et al. 2010) and *Arid3a* (Peeper et al. 2002). Both genes peak mid-gestation in the whole mouse embryo. Thus, these genes may further populate the let-7-regulated oncofetal network.

The up-regulation of a mid-gestation program in miRNA-deficient somatic cells suggests that the inactivation of these embryonic genes in adult tissue is maintained in a deliberately reversible state. Several of these genes, such as *Hmga2* and *Igf2bp1*, play important roles in metabolism and proliferation (Viswanathan et al. 2009; Viswanathan and Daley 2010; Zhu et al. 2010; Frost and Olson 2011) and may be transiently activated, perhaps through down-regulation of let-7 or other miRNAs in somatic tissue, to promote injury repair or growth. This possibility is supported by a recent study demonstrating the importance of an HMGA2–IGF2BP2 axis in muscle regeneration in adult animals (Li et al. 2012). The over-expression of these oncofetal genes in tumors may reflect the inappropriate ectopic activation of an otherwise native, context-specific process regulated dynamically by miRNAs. Notably, the up-regulation of this discrete, embryonic program is compatible with mesenchymal cell identity, consistent with previous reports that gene expression consists of separable modules that

can be coactivated in various permutations (Wong et al. 2008; Kim et al. 2010).

Our results also extend the current model of let-7 function in mammalian development. Our data suggest a stage in the embryo, from E8.5 to E10.5, in which the embryo has progressed well past a naive ESC state, thus shutting off the miR-290 family, but has not yet globally activated let-7 (Fig. 7). This possibility is consistent with recent findings that let-7 promotes development of the emerging mesoderm and ectoderm of mouse and *Xenopus* embryos (Colas et al. 2012). We postulate that let-7 plays a role beyond inhibition of pluripotency and represses mid-gestation programs to ensure a forward momentum during development, consistent with observations in nematodes that let-7 and lin-4 mutant animals reiterate post-pluripotency larval stages (Lee et al. 1993; Reinhart et al. 2000).

Related to the role of let-7 in developmental timing, we identified *Nr6a1*, a potential functional ortholog of nematode *daf-12*, as a target of let-7. In our study, *Nr6a1* represses genes that become activated as the embryo matures, suggesting that precise dosage of *Nr6a1* is critical to developmental timing. Consistent with this observation, overexpression of *Nr6a1* results in posterior defects and altered somite formation in *Xenopus* embryos (David et al. 1998). Thus, *Nr6a1* and let-7 are likely sequentially activated and mutually antagonistic to ensure the proper chronology of gene expression in the mid-gestation embryo.

In conclusion, our findings support the hypothesis that the tumor-suppressive properties of let-7 are coupled to its repression, in somatic tissues, of metabolic embryonic programs. Furthermore, the global loss of miRNAs in adult tissue leads to transcriptional effects that reinforce specific gene expression programs. From a therapeutic standpoint, the inhibition of tumor growth may not be feasible by the inactivation of only a single miRNA target and may instead require delivery of individual synthetic tumor-suppressive miRNAs to inactivate full gene expression networks.




Figure 7. Summary of let-7 and target expression in the whole mouse embryo. Let-7 targets peak mid-gestation (around E8.5–E10.5), after down-regulation of the ESC-specific miR-290 family. Expression of mature let-7 becomes detectable in the whole embryo around E10.5 and steadily increases in level, concomitant with down-regulation of high-confidence let-7 targets such as *Nr6a1*, identified in this study. Targets of *Nr6a1* identified in this study increase as the embryo matures and positively correlate with let-7 in the whole mouse embryo.

Gurtan et al.

Materials and methods

Complete protocols are provided in the Supplemental Material and are also available on request. Microarray and sequencing data are available under Gene Expression Omnibus accession number GSE44163.

Cell culture conditions

Murine MSCs were passaged in α -MEM supplemented with 10% FBS and penicillin/streptomycin as described previously (Gurtan et al. 2012; Ravi et al. 2012). Sarcoma cells were passaged in DMEM supplemented with 10% FBS, L-glutamine, and penicillin/streptomycin as described previously (Ravi et al. 2012).

Transfections and infections

For siRNA transfections, cells were transfected with HiPerfect reagent (Qiagen) and 20 nM siCtrl (Non-Targeting siRNA No. 2, Thermo Scientific Dharmacon), synthetic let-7g siRNA synthesized as perfectly complementary siRNA duplex (custom RNA synthesis service, Thermo Scientific Dharmacon), or gene-specific siRNA against *Nr6a1* (Qiagen). Forty-eight hours after transfection, cells were harvested. Total RNA was isolated with an RNeasy kit (Qiagen) for qPCR or mRNA-seq. Total protein was isolated with radio immunoprecipitation assay (RIPA) buffer supplemented with protease inhibitor tablets (Roche). siRNA experiments were carried out in biological triplicate in a single pair of clonal isogenic MSCs.

For infections, ϕ NX (Phoenix) cells were transfected with Lipofectamine 2000 (Invitrogen) and either pMMP-puro-vector or pMMP-puro-Flag-HA-NR6A1 plasmid. *Nr6a1* cDNA (Isoform 1) was cloned from Dicer knockout MSCs. Viral supernatant was cleared with a 0.45- μ m syringe filter. Subconfluent MSCs were incubated with viral supernatant at a multiplicity of infection ≤ 1 and 8 μ g of polybrene (Sigma) overnight and then selected with 2.5 μ g of puromycin. Prior to being used for experiments, transduced MSCs were passaged under selection for ~ 2 wk. Infections were carried out on two independent clones of Dicer wild-type MSCs, thus representing biological duplicates.

Western blot

RIPA lysates were diluted twofold with 2 \times Laemmli loading buffer with 5% β -mercaptoethanol and then boiled for 10 min. Samples were separated in 4%–12% Bis-Tris denaturing polyacrylamide Novex gradient gels (Invitrogen) in an XCell SureLock apparatus (Invitrogen) and transferred to a polyvinylidene fluoride (PVDF) membrane in a Mini Trans-Blot wet transfer apparatus (Bio-Rad). Membranes were blocked with 5% milk in 1 \times Tris-buffered saline with 0.1% Tween 20 (TBST), incubated overnight at 4°C with primary antibody diluted in 5% milk/TBST, washed three times with 1 \times TBST, incubated for 1 h at room temperature with secondary antibody conjugated to horseradish peroxidase (GE Healthcare Life Sciences), washed three times, incubated briefly with Western Lightning Plus-ECL (PerkinElmer), and visualized on film (Kodak).

The following rabbit polyclonal antibodies were used: anti-IGF2BP1 (MBL International), anti-IGF2BP2 (MBL International), anti-IGF2BP3 (MBL International), anti-HMGA2 (Cell Signaling Technology), and anti-p107 (Santa Cruz Biotechnology).

qPCR

Total RNA was treated with a TURBO DNA-free kit (Ambion). cDNA was generated with oligo-dT primer using a SuperScript III

first strand synthesis system (Invitrogen). Gene expression was analyzed with Power SYBR Green (Applied Biosystems).

Microarray analysis

For MSCs, two clones of Dicer wild-type and their four derivative clones of Dicer knockout cells were grown to confluence in six-well plates, after which total RNA was prepared with QIAzol (Qiagen). A third Dicer wild-type clone, from which no Dicer knockout cells were available, was also analyzed initially but then subsequently excluded as an outlier. For sarcoma samples, Dicer heterozygous and Dicer knockout cells were grown to confluence in T25s, and total RNA was prepared with an RNeasy kit (Qiagen). Biotinylated cRNA was prepared using the Affymetrix GeneChip WT Sense Target Labeling and Control Reagents kit and hybridized to Affymetrix Mouse 430_2_3' arrays (sarcoma cell lines) or Mouse MoEx-1_0-st exon arrays (MSCs) at the BioMicroCenter at MIT.

RNA-seq

Cloning and sequencing of small RNAs were carried out as described previously (Gurtan et al. 2012; Ravi et al. 2012). mRNA-seq was carried out with total RNA purified with the RNeasy reagent (Qiagen) and DNase-treated with TURBO DNase (Ambion). Samples were prepared for Illumina sequencing at the BioMicroCenter at MIT.

ChIP-seq

ChIP experiments were carried out as described previously (Rahl et al. 2010). In summary, Dicer wild-type and Dicer knockout MSCs were grown as described above and cross-linked for 10 min at room temperature by the addition of one-tenth of the volume of 11% formaldehyde solution (11% formaldehyde, 50 mM HEPES at pH 7.3, 100 mM NaCl, 1 mM EDTA at pH 8.0, 0.5 mM EGTA at pH 8.0) to the growth medium. Cells were washed twice with PBS, supernatant was aspirated, and the cell pellet was flash-frozen in liquid nitrogen. Frozen cross-linked cells were stored at -80°C . For histone mark immunoprecipitation, the following antibodies were used: Histone H3K4me3, Millipore 07-473, lot number DAM1731494 (7.5 μ L per ChIP); Histone H3K36me3, Abcam ab9050-100, lot number 136352; Histone H3K27me3, Abcam ab6002-100, lot number 49749. For immunoprecipitation of Flag-HA-NR6A1, anti-HA (Roche, 11867423001) was used.

Acknowledgments

We thank members of the Sharp laboratory for helpful discussions and experimental assistance. Specifically, we thank Timothy Kelly for generating the doxycycline-inducible Flag-HA-Ago2 construct, and Jesse Zamudio and Mohini Jangi for help with Flag-HA-NR6A1 ChIP. We thank Alla Leshinsky, Richard Cook, and the rest of the Swanson Biotechnology Center at the David H. Koch Institute for Integrative Cancer Research at MIT for Illumina and other sequencing services. We thank Stuart Levine and the staff of the BioMicroCenter at MIT for preparation of RNA-seq and ChIP-seq samples. This work was supported by NIH grant RO1-GM34277 (to P.A.S.), NCI grant PO1-CA42063 (to P.A.S.), RO1-HG002668 (to R.A.Y.), and the NCI Cancer Center Support (core) grant P30-CA14051. A.M.G. acknowledges support from the Leukemia and Lymphoma Society Grant 5198-09. A.M.G., with contributions from A.R., designed the study. A.M.G., A.R., P.B.R., A.D.B., and C.K.J. performed experiments. P.B.R., under the supervision of R.A.Y., carried out ChIP of

histone marks. A.D.B. designed and carried out the CLIP-seq experiments. A.M.G., A.R., A.D.B., A.B., and C.A.W. carried out computational analyses. A.B. and C.A.W. performed the informatics for the microarray and sequencing data. A.M.G. wrote the paper. P.A.S. provided supervision and assisted with manuscript preparation. All authors reviewed and approved the manuscript.

References

- Alajez NM, Shi W, Wong D, Lenarduzzi M, Waldron J, Weinreb I, Liu FF. 2012. Lin28b promotes head and neck cancer progression via modulation of the insulin-like growth factor survival pathway. *Oncotarget* **3**: 1641–1652.
- Ambros V. 2011. MicroRNAs and developmental timing. *Curr Opin Genet Dev* **21**: 511–517.
- Andl T, Murchison EP, Liu F, Zhang Y, Yunta-Gonzalez M, Tobias JW, Andl CD, Seykora JT, Hannon GJ, Millar SE. 2006. The miRNA-processing enzyme dicer is essential for the morphogenesis and maintenance of hair follicles. *Curr Biol* **16**: 1041–1049.
- Bartel DP, Chen CZ. 2004. Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. *Nat Rev Genet* **5**: 396–400.
- Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ. 2003. Dicer is essential for mouse development. *Nat Genet* **35**: 215–217.
- Boyerinas B, Park SM, Shomron N, Hedegaard MM, Vinther J, Andersen JS, Feig C, Xu J, Burge CB, Peter ME. 2008. Identification of let-7-regulated oncofetal genes. *Cancer Res* **68**: 2587–2591.
- Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME. 2010. The role of let-7 in cell differentiation and cancer. *Endocr Relat Cancer* **17**: F19–F36.
- Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. 2003. bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in *Drosophila*. *Cell* **113**: 25–36.
- Calabrese JM, Seila AC, Yeo GW, Sharp PA. 2007. RNA sequence analysis defines Dicer's role in mouse embryonic stem cells. *Proc Natl Acad Sci* **104**: 18097–18102.
- Chi SW, Zang JB, Mele A, Darnell RB. 2009. Argonaute HITS-CLIP decodes microRNA–mRNA interaction maps. *Nature* **460**: 479–486.
- Chung AC, Katz D, Pereira FA, Jackson KJ, DeMayo FJ, Cooney AJ, O'Malley BW. 2001. Loss of orphan receptor germ cell nuclear factor function results in ectopic development of the tail bud and a novel posterior truncation. *Mol Cell Biol* **21**: 663–677.
- Colas AR, McKeithan WL, Cunningham TJ, Bushway PJ, Garmire LX, Duester G, Subramaniam S, Mercola M. 2012. Whole-genome microRNA screening identifies let-7 and mir-18 as regulators of germ layer formation during early embryogenesis. *Genes Dev* **26**: 2567–2579.
- David R, Joos TO, Dreyer C. 1998. Anteroposterior patterning and organogenesis of *Xenopus laevis* require a correct dose of germ cell nuclear factor (xGCNF). *Mech Dev* **79**: 137–152.
- Dugas JC, Cuellar TL, Scholze A, Ason B, Ibrahim A, Emery B, Zamanian JL, Foo LC, McManus MT, Barres BA. 2010. Dicer1 and miR-219 Are required for normal oligodendrocyte differentiation and myelination. *Neuron* **65**: 597–611.
- Ebert MS, Sharp PA. 2012. Roles for microRNAs in conferring robustness to biological processes. *Cell* **149**: 515–524.
- Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, Ciarmiello A, Pallante P, Arra C, Melillo RM, et al. 2006. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. *Cancer Cell* **9**: 459–471.
- Frost RJ, Olson EN. 2011. Control of glucose homeostasis and insulin sensitivity by the Let-7 family of microRNAs. *Proc Natl Acad Sci* **108**: 21075–21080.
- Fuhrmann G, Chung AC, Jackson KJ, Hummelke G, Baniahmad A, Sutter J, Sylvester I, Scholer HR, Cooney AJ. 2001. Mouse germline restriction of Oct4 expression by germ cell nuclear factor. *Dev Cell* **1**: 377–387.
- Ghildiyal M, Zamore PD. 2009. Small silencing RNAs: An expanding universe. *Nat Rev Genet* **10**: 94–108.
- Gu P, LeMenuet D, Chung AC, Mancini M, Wheeler DA, Cooney AJ. 2005. Orphan nuclear receptor GCNF is required for the repression of pluripotency genes during retinoic acid-induced embryonic stem cell differentiation. *Mol Cell Biol* **25**: 8507–8519.
- Gurtan AM, Sharp PA. 2013. The role of miRNAs in regulating gene expression networks. *J Mol Biol*. doi: 10.1016/j.jmb.2013.03.007.
- Gurtan AM, Lu V, Bhutkar A, Sharp PA. 2012. In vivo structure–function analysis of human Dicer reveals directional processing of precursor miRNAs. *RNA* **18**: 1116–1122.
- Hammell CM, Karp X, Ambros V. 2009. A feedback circuit involving let-7-family miRNAs and DAF-12 integrates environmental signals and developmental timing in *Caenorhabditis elegans*. *Proc Natl Acad Sci* **106**: 18668–18673.
- Hansen TV, Hammer NA, Nielsen J, Madsen M, Dalbaeck C, Wewer UM, Christiansen J, Nielsen FC. 2004. Dwarfism and impaired gut development in insulin-like growth factor II mRNA-binding protein 1-deficient mice. *Mol Cell Biol* **24**: 4448–4464.
- Harfe BD, McManus MT, Mansfield JH, Hornstein E, Tabin CJ. 2005. The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. *Proc Natl Acad Sci* **102**: 10898–10903.
- Herranz H, Cohen SM. 2010. MicroRNAs and gene regulatory networks: Managing the impact of noise in biological systems. *Genes Dev* **24**: 1339–1344.
- Hirning-Folz U, Wilda M, Rippe V, Bullerdiek J, Hameister H. 1998. The expression pattern of the Hmgic gene during development. *Genes Chromosomes Cancer* **23**: 350–357.
- Irie N, Kuratani S. 2011. Comparative transcriptome analysis reveals vertebrate phylotypic period during organogenesis. *Nat Commun* **2**: 248.
- Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. 2005. RAS is regulated by the let-7 microRNA family. *Cell* **120**: 635–647.
- Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, et al. 2007. The let-7 microRNA represses cell proliferation pathways in human cells. *Cancer Res* **67**: 7713–7722.
- Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, Jenuwein T, Livingston DM, Rajewsky K. 2005. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. *Genes Dev* **19**: 489–501.
- Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH. 2010. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. *Cell* **143**: 313–324.
- Koralov SB, Muljo SA, Galler GR, Krek A, Chakraborty T, Kanellopoulou C, Jensen K, Cobb BS, Merkenschlager M, Rajewsky N, et al. 2008. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. *Cell* **132**: 860–874.
- Lee YS, Dutta A. 2007. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. *Genes Dev* **21**: 1025–1030.

Gurtan et al.

- Lee RC, Feinbaum RL, Ambros V. 1993. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell* **75**: 843–854.
- Leung AK, Young AG, Bhutkar A, Zheng GX, Bosson AD, Nielsen CB, Sharp PA. 2011. Genome-wide identification of Ago2 binding sites from mouse embryonic stem cells with and without mature microRNAs. *Nat Struct Mol Biol* **18**: 237–244.
- Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q, Ramanujan K, Shavlakadze T, Eash JK, Scaramozza A, Goddeeris MM, et al. 2012. An HMGA2-IGF2BP2 axis regulates myoblast proliferation and myogenesis. *Dev Cell* **23**: 1176–1188.
- Marson A, Levine SS, Cole MF, Frampton GM, Brambrink T, Johnstone S, Guenther MG, Johnston WK, Wernig M, Newman J, et al. 2008. Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. *Cell* **134**: 521–533.
- Mayr C, Bartel DP. 2009. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell* **138**: 673–684.
- Mayr C, Hemann MT, Bartel DP. 2007. Disrupting the pairing between *let-7* and *Hmga2* enhances oncogenic transformation. *Science* **315**: 1576–1579.
- Melton C, Judson RL, Belloch R. 2010. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. *Nature* **463**: 621–626.
- Muljo SA, Ansel KM, Kanellopoulou C, Livingston DM, Rao A, Rajewsky K. 2005. Aberrant T cell differentiation in the absence of Dicer. *J Exp Med* **202**: 261–269.
- Murchison EP, Partridge JF, Tam OH, Cheloufi S, Hannon GJ. 2005. Characterization of Dicer-deficient murine embryonic stem cells. *Proc Natl Acad Sci* **102**: 12135–12140.
- Nimmo RA, Slack FJ. 2009. An elegant miRror: MicroRNAs in stem cells, developmental timing and cancer. *Chromosoma* **118**: 405–418.
- O'Rourke JR, Georges SA, Seay HR, Tapscott SJ, McManus MT, Goldhamer DJ, Swanson MS, Harfe BD. 2007. Essential role for Dicer during skeletal muscle development. *Dev Biol* **311**: 359–368.
- Peeper DS, Shvarts A, Brummelkamp T, Douma S, Koh EY, Daley GQ, Bernards R. 2002. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. *Nat Cell Biol* **4**: 148–153.
- Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, Sharp PA, Young RA. 2010. c-Myc regulates transcriptional pause release. *Cell* **141**: 432–445.
- Ravi A, Gurtan AM, Kumar MS, Bhutkar A, Chin C, Lu V, Lees JA, Jacks T, Sharp PA. 2012. Proliferation and tumorigenesis of a murine sarcoma cell line in the absence of DICER1. *Cancer Cell* **21**: 848–855.
- Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvi AE, Horvitz HR, Ruvkun G. 2000. The 21-nucleotide *let-7* RNA regulates developmental timing in *Caenorhabditis elegans*. *Nature* **403**: 901–906.
- Schulman BR, Esquela-Kerscher A, Slack FJ. 2005. Reciprocal expression of *lin-41* and the microRNAs *let-7* and *mir-125* during mouse embryogenesis. *Dev Dyn* **234**: 1046–1054.
- Shapiro JS, Langlois RA, Pham AM, Tenoever BR. 2012. Evidence for a cytoplasmic microprocessor of pri-miRNAs. *RNA* **18**: 1338–1346.
- Taher L, Collette NM, Muruges D, Maxwell E, Ovcharenko I, Loots GG. 2011. Global gene expression analysis of murine limb development. *PLoS ONE* **6**: e28358.
- Takebe A, Era T, Okada M, Martin Jakt L, Kuroda Y, Nishikawa S. 2006. Microarray analysis of PDGFR α^+ populations in ES cell differentiation culture identifies genes involved in differentiation of mesoderm and mesenchyme including ARID3b that is essential for development of embryonic mesenchymal cells. *Dev Biol* **293**: 25–37.
- Tessier CR, Doyle GA, Clark BA, Pitot HC, Ross J. 2004. Mammary tumor induction in transgenic mice expressing an RNA-binding protein. *Cancer Res* **64**: 209–214.
- Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, et al. 2010. Regression of murine lung tumors by the *let-7* microRNA. *Oncogene* **29**: 1580–1587.
- Viswanathan SR, Daley GQ. 2010. *Lin28*: A microRNA regulator with a macro role. *Cell* **140**: 445–449.
- Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, et al. 2009. *Lin28* promotes transformation and is associated with advanced human malignancies. *Nat Genet* **41**: 843–848.
- Vitobello A, Ferretti E, Lampe X, Vilain N, Ducret S, Ori M, Spetz JF, Selleri L, Rijli FM. 2011. Hox and Pbx factors control retinoic acid synthesis during hindbrain segmentation. *Dev Cell* **20**: 469–482.
- Wang Y, Medvid R, Melton C, Jaenisch R, Belloch R. 2007. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. *Nat Genet* **39**: 380–385.
- Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. 2008. Module map of stem cell genes guides creation of epithelial cancer stem cells. *Cell Stem Cell* **2**: 333–344.
- Wu C, Orozco C, Boyer J, Leglise M, Goodale J, Batalov S, Hodge CL, Haase J, Janes J, Huss JW III, et al. 2009. BioGPS: An extensible and customizable portal for querying and organizing gene annotation resources. *Genome Biol* **10**: R130.
- Wu C, Macleod I, Su AI. 2013. BioGPS and MyGene.info: Organizing online, gene-centric information. *Nucleic Acids Res* **41**: D561–D565.
- Yan ZH, Medvedev A, Hirose T, Gotoh H, Jetten AM. 1997. Characterization of the response element and DNA binding properties of the nuclear orphan receptor germ cell nuclear factor/retinoid receptor-related testis-associated receptor. *J Biol Chem* **272**: 10565–10572.
- Yi R, O'Carroll D, Pasolli HA, Zhang Z, Dietrich FS, Tarakhovskiy A, Fuchs E. 2006. Morphogenesis in skin is governed by discrete sets of differentially expressed microRNAs. *Nat Genet* **38**: 356–362.
- Zaidi MR, Okada Y, Chada KK. 2006. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. *Cancer Res* **66**: 7453–7459.
- Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, Paik JH, Zhang H, Xiao Y, Perry SR, et al. 2010. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. *Cancer Cell* **17**: 497–509.
- Zhou X, Benson KE, Ashar HR, Chada K. 1995. Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. *Nature* **376**: 771–774.
- Zhu H, Shah S, Shyh-Chang N, Shinoda G, Einhorn WS, Viswanathan SR, Takeuchi A, Grasmann C, Rinn JL, Lopez MF, et al. 2010. *Lin28a* transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. *Nat Genet* **42**: 626–630.
- Zhu H, Shyh-Chang N, Segre AV, Shinoda G, Shah SP, Einhorn WS, Takeuchi A, Engreitz JM, Hagan JP, Kharas MG, et al. 2011. The *Lin28/let-7* axis regulates glucose metabolism. *Cell* **147**: 81–94.